obstructive sleep apnea-hypopnea syndrome
Conditions
Interventions
Dexmedetomidine (D) group:Dexmedetomidine 0.2 ml/kg (diluted to 2.5ug/ml dexmedetomidine) administered intravenously at induction of anesthesia
Nalbuphine (N) group:0.2 ml/kg of nalbuphine (diluted to 1.5 mg/ml nalbuphine) administered sedately at induction of anesthesia
Sponsors
Shanghai Children's Hospital
Eligibility
Sex/Gender
All
Age
3 Years to 12 Years
Inclusion criteria
Inclusion criteria: 1) ASA Level I-II ; 2) Age 3-12 years ; ;3) Body mass index (BMI) >=15.5 kg/m^2 and <=24.5 kg/m^2 with weight over 12 kg;
Exclusion criteria
Exclusion criteria: 1) Hypersensitivity to the drugs used in this study or opioid abuse; 2) Severe obstructive sleep apnea syndrome and cardiac arrhythmia; 3) Combined serious cardiac, hepatic, renal dysfunction and mental abnormality; 4) Fever higher than 38°C or acute upper respiratory tract infection and bronchial asthma in the 24 hours before surgery.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of moderate to severe pain on swallowing within 4 hours after surgery; | — |
Secondary
| Measure | Time frame |
|---|---|
| FLACC score (3-6 years) or NRS score (7-12 years) at rest and during swallowing at 0h, 0.5h, 2h, and 4h postoperatively;Incidence of postoperative adverse reactions;Number of children requiring additional postoperative analgesia;Incidence of agitation while in the PACU in both groups of children; | — |
Countries
China
Contacts
Public ContactHongyun Li
Shanghai Children's Hospital
Outcome results
None listed